Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

Danielle Bucco
Published: Thursday, Jun 29, 2017

Jean Jacques Grob, MD, PhD

Jean Jacques Grob, MD, PhD

Patients with stage III melanoma who receive 10 mg/kg of adjuvant ipilimumab (Yervoy) see efficacious results, but at a much higher cost of toxicity compared to lower doses of the CTLA-4 inhibitor.

“There is a high proportion of grade 3 to 5 adverse events with 10 mg/kg of ipilimumab, especially in the adjuvant setting,” said Jean Jacques Grob, MD, PhD, who gave a presentation on ipilimumab at the 2017 European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

Due to these toxicities, Grob sees a 10 mg/kg dose of ipilimumab slowly leaving the treatment landscape for these patients. However, lower doses and combinations continue to be investigated and show promise.

In an interview with OncLive, Grob, professor of Dermatology at the Hospital de la Timone, discussed the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

OncLive: Can you provide an overview of your presentation on ipilimumab? 

Grob: I discussed the ratio between tolerability and efficacy of the different dosages of ipilimumab in the adjuvant setting. I covered different points of view, the first being that toxicity is proportional to the dose. We currently are using 3 different dosages: 10 mg/kg, 3 mg/kg, and 1mg/kg. 

In the adjuvant setting, only 10 mg/kg has been studied so far, but studies are ongoing with all the dosages. The toxicity that has been observed in the adjuvant trial with 10 mg/kg was very high. Despite the very good impact on relapse-free survival and overall survival, there is a big debate, for many reasons, about whether it is reasonable to use the dosage in patients for adjuvant therapy.

First, a lot of patients will be treated even if they do not need it because we are unable to select the right patient, individually. Secondly, we don’t know whether the fact that giving an adjuvant therapy with ipilimumab is preventing the future efficacy of immunotherapy, in general, when it might be needed in an advanced stage with the same patient. We don’t know whether it is good or bad to treat the patient early or to just wait for metastatic disease and then treat the metastatic disease. 

Are there any ongoing studies investigating those challenges?

There is a panel of studies, but that is not covering all of the questions we continue to ask ourselves. However, the trials mainly focus on the dosage of ipilimumab and even consider the question of whether we should treat a patient early or late.

Can you discuss the safety profile of ipilimumab?

There is a high proportion of grade 3 to 5 adverse events with 10 mg/kg, especially in the adjuvant setting. We have observed that the toxicity for a given dose is much higher when the drug is given in the adjuvant setting than when it's given in the metastatic setting. This is probably because the immune system is more active in patients with bigger tumor loads. 

Ipilimumab is being looked at in combination with nivolumab (Opdivo). Are there any other combinations that are showing promise?

There are other combinations. First of all, ipilimumab has also been tested with pembrolizumab (Keytruda), but this is much less advanced in terms of trials. Ipilimumab is tested at 1 mg/kg, which will be decreasing the toxicity profile and perhaps not decreasing the efficacy too much but this has to be tested. This is not yet in the adjuvant setting but ipilimumab is combined with different types of molecules.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication